La curiéthérapie endobronchique (l'expérience du Centre Antoine Lacassagne)

NICE-BU Médecine Odontologie (060882102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Enhancing the flexibility of pipeline infrastructure to cope with heavy oils: Incremental thermal retrofit

Pipelines that were well designed for conventional oils may not be able to cope with a transition to heavy oils without some retrofit adaptation, as the increased pressure drop may exceed constraints and force some reduction in throughput. In this paper, ways of enhancing the utilization of existing, capital intensive infrastructure by small, incremental additions are explored. A thermo-hydraulic pipeline model for a buried pipeline is presented. The model is then applied to a case study involving a section of the important, recently built Russia-China ESPO pipeline, for which a gradual shift from the current (design) light oil to heavier oils is considered. A number of thermal retrofit scenarios are proposed and assessed which involve the incremental supply of additional heat at selected points. These scenarios go from pre-heating of the oil at entrance to use of single and multiple intermediate heating stations. The heating duty requirements for each case are calculated. The results show that a careful use of such thermal management techniques can significantly mitigate the reduction in throughput that would otherwise be required, leading to significant economic savings in operations. It is highlighted that the development of adaptable, modular low-cost heating technologies would make this approach significantly advantageous over other alternatives

Effect of Mono-, Di-, and Triethylene Glycol on the Activity of Phosphate-Doped NiMo/Al2O3 Hydrotreating Catalysts

The effect of glycols on the catalytic properties of phosphate-doped NiMo/Al2O3 catalysts in the hydrotreating of straight-run gas oil (SRGO) was studied. The NiMo(P)/Al2O3 catalysts were prepared using ethylene glycol (EG), diethylene glycol (DEG), and triethylene glycol (TEG) as additives. The organic agent was introduced into the aqueous impregnation solution obtained by the dissolving of MoO3 in H3PO4 solution, followed by Ni(OH)2 addition. The Raman and UV–Vis studies show that the impregnation solution contains diphosphopentamolybdate HxP2Mo5O23(6−x)− and Ni(H2O)62+, and that these ions are not affected by the presence of glycols. When the impregnation solution comes in contact with the γ-Al2O3 surface, HxP2Mo5O23(6−x)− is decomposed completely. The catalysts were characterized by Raman spectroscopy, low-temperature N2 adsorption, X-ray photoelectron spectroscopy, and transmission electron microscopy. It is shown that the sulfide catalysts prepared with glycols display higher activity in the hydrotreating of straight-run gas oil than the NiMoP/Al2O3 catalyst prepared without the additive. The hydrodesulfurization and hydrodenitrogenation activities depend on the glycol type and are decreased in the following order: NiMoP-DEG/Al2O3 > NiMoP-EG/Al2O3 > NiMoP-TEG/Al2O3 > NiMoP/Al2O3. The higher activity of NiMoP-DEG/Al2O3 can be explained with the higher dispersion of molybdenum on the surface of the catalyst in the sulfide state

Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels

1. In many cancer patients, 5-fluorouracil (5-FUra) treatment is toxic and even causes death. Nevertheless, all patients are subjected to a standard therapy regimen because there is no reliable way to identify beforehand those patients who are predisposed to 5-FUra-induced toxicity. In this study, we identified the dihydrouracil/uracil (UH2/Ura) ratio in plasma or urine as a potential biomarker reflecting the activity of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-FUra metabolism. 2. UH2/Ura ratios were measured by high-performance liquid chromatography tandem triple quadrupole mass spectrometry (HPLC-MS/MS) in both healthy subjects (n=55) and in patients (n=20) diagnosed with grade I/II gestational trophoblastic tumours. In addition, rats (n=18) were used as an animal model to verify a correlation between UH2/Ura ratios and DPD levels in the liver. 3. A significant circadian rhythm was observed in UH2/Ura ratios in healthy subjects, whereas a disrupted rhythm occurred in cancer patients who were continuously infused with a high dose of 5-FUra. In rats, UH2/Ura ratios, liver DPD levels and PBMC DPD levels showed a definite circadian rhythm. Significant linear correlations with liver DPD levels were demonstrated for plasma UH2/Ura ratios (r=0.883, P<0.01), urine UH2/Ura ratios (r=0.832, P<0.01) and PBMC DPD levels (r=0.859, P<0.01). 4. The UH2/Ura ratio in biological fluid was significantly correlated with liver DPD levels; hence, this ratio could be a potential biomarker to identify patients with a deficiency in DPD